The new bispecific antibody treatment for lymphoma, ‘Lunsumio’, will soon land in Korea.

According to industry sources, the Ministry of Food and Drug Safety is in its last stages of review for the product approval of Roche Korea's follicular lymphoma drug Lunsumio (mosunetuzumab), which was designated as the first drug subject to Korea’s Global Innovative products on Fast Track (GIFT) system.

Lunsumio was approved by the US Food and Drug Administration in December last year for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

The drug is a CD20xCD3 T-cell engaging bispecific antibody that bind